Immunterápia az urológiai daganatok kezelésében

Translated title of the contribution: Immunotherapy in the treatment of genitourinary cancers

L. Géczi, A. Ladányi, Tímea Vajdics, Zsófia Küronya, Krisztina Bíró, Fruzsina Gyergyay, Tamás Martin, Krisztián Nagyiványi

Research output: Contribution to journalReview article

Abstract

In this clinical review we provide information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival. Based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer. Regarding germ cell tumors basic research is ongoing.

Original languageHungarian
Pages (from-to)41-45
Number of pages5
JournalMagyar Onkologia
Volume60
Issue number1
Publication statusPublished - Mar 2 2016

Fingerprint

Urogenital Neoplasms
Immunotherapy
Renal Cell Carcinoma
Prostatic Neoplasms
Hope
Germ Cell and Embryonal Neoplasms
Castration
Standard of Care
Urinary Bladder Neoplasms
Protein-Tyrosine Kinases
Disease-Free Survival
Therapeutics
Monoclonal Antibodies
Survival
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Géczi, L., Ladányi, A., Vajdics, T., Küronya, Z., Bíró, K., Gyergyay, F., ... Nagyiványi, K. (2016). Immunterápia az urológiai daganatok kezelésében. Magyar Onkologia, 60(1), 41-45.

Immunterápia az urológiai daganatok kezelésében. / Géczi, L.; Ladányi, A.; Vajdics, Tímea; Küronya, Zsófia; Bíró, Krisztina; Gyergyay, Fruzsina; Martin, Tamás; Nagyiványi, Krisztián.

In: Magyar Onkologia, Vol. 60, No. 1, 02.03.2016, p. 41-45.

Research output: Contribution to journalReview article

Géczi, L, Ladányi, A, Vajdics, T, Küronya, Z, Bíró, K, Gyergyay, F, Martin, T & Nagyiványi, K 2016, 'Immunterápia az urológiai daganatok kezelésében', Magyar Onkologia, vol. 60, no. 1, pp. 41-45.
Géczi L, Ladányi A, Vajdics T, Küronya Z, Bíró K, Gyergyay F et al. Immunterápia az urológiai daganatok kezelésében. Magyar Onkologia. 2016 Mar 2;60(1):41-45.
Géczi, L. ; Ladányi, A. ; Vajdics, Tímea ; Küronya, Zsófia ; Bíró, Krisztina ; Gyergyay, Fruzsina ; Martin, Tamás ; Nagyiványi, Krisztián. / Immunterápia az urológiai daganatok kezelésében. In: Magyar Onkologia. 2016 ; Vol. 60, No. 1. pp. 41-45.
@article{ae2eb0c8788245d3a158a1dbd5ccd0f8,
title = "Immunter{\'a}pia az urol{\'o}giai daganatok kezel{\'e}s{\'e}ben",
abstract = "In this clinical review we provide information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival. Based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer. Regarding germ cell tumors basic research is ongoing.",
author = "L. G{\'e}czi and A. Lad{\'a}nyi and T{\'i}mea Vajdics and Zs{\'o}fia K{\"u}ronya and Krisztina B{\'i}r{\'o} and Fruzsina Gyergyay and Tam{\'a}s Martin and Kriszti{\'a}n Nagyiv{\'a}nyi",
year = "2016",
month = "3",
day = "2",
language = "Hungarian",
volume = "60",
pages = "41--45",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Immunterápia az urológiai daganatok kezelésében

AU - Géczi, L.

AU - Ladányi, A.

AU - Vajdics, Tímea

AU - Küronya, Zsófia

AU - Bíró, Krisztina

AU - Gyergyay, Fruzsina

AU - Martin, Tamás

AU - Nagyiványi, Krisztián

PY - 2016/3/2

Y1 - 2016/3/2

N2 - In this clinical review we provide information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival. Based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer. Regarding germ cell tumors basic research is ongoing.

AB - In this clinical review we provide information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer but had no effect on progression-free survival. Based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer. Regarding germ cell tumors basic research is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=85055960191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055960191&partnerID=8YFLogxK

M3 - Review article

VL - 60

SP - 41

EP - 45

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -